1. Two doses of the Pfizer-BioNTech BNT162b2 vaccine were linked to high immediate protection again severe acute respiratory syndrome coronary...

1. One dose of Ad26.COV2.S (Johnson & Johnson) provided some protection against moderate to severe Covid-19-related infection and medical intervention....

1. A two-dose regimen of BNT162b2 at 10μg elicits a sufficient immune response in children 5 – 11 years of...

1. Adding a mask recommendation to other public measures did not reduce the SARS-Cov-2 infection by more than 50%. 2....

1. The Canadian Syncope Risk Score was superior when compared to the Osservatorio Epidemiologico della Sincope nel Lazio (OESIL) score...

1. Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death regardless of frailty status. 2. Dapagliflozin improved quality...

1. In infants undergoing endotracheal intubation, nasal high-flow therapy improved the likelihood of successful intubation on the first attempt. 2....

1. Patients receiving the fourth dose of BNT162b2 (Pfizer-BioNTech) showed reduced rates of symptomatic Covid-19 infection and hospitalization compared to...

1. The prefusion F protein of RSV (RSVpreF) vaccine produces neutralizing antibodies against RSV in both the serum of the...

1. In patients with stable chest pain and intermediate pretest probability of coronary artery disease (CAD), there was no difference...